Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints NIH’s Gary Nabel as chief scientific officer

He previously headed vaccine research centre of the US National Institute of Allergy and Infectious Diseases

Gary Nabel, SanofiDr Gary Nabel has left US medical research centre the National Institutes of Health (NIH) to join Sanofi as senior VP, chief scientific officer and deputy to the president for global R&D.

In his new role, he will hold responsibility for Sanofi's scientific strategy for all of its units, including pharmaceuticals, animal health and vaccines, and will focus on improving translational approaches in research.

Dr Nabel will be based at Sanofi's offices in Cambridge, Massachusetts – the city he studied in during his time as Harvard University.

“I am very excited that Dr Nabel will join Sanofi's R&D organisation,” said Dr Elias Zerhouni, president, global R&D, Sanofi. “Our challenges today require that we re-invent our R&D model. Gary's experience will be invaluable to help us achieve this goal.”

Dr Nabel leaves the NIH, which is part of the US government's department of health, after 13 years as director of the vaccine research centre (VRC) of the National Institute of Allergy and Infectious Diseases.

During this period, he provided overall direction of the VRC, including the development of notable vaccine strategies against HIV, ebola, bird flu and SARS.

Prior to joining the NIH, Dr Nabel held several senior research and academic positions, including as director of the centre for gene therapy and co-director of the centre for molecular medicine at the University of Michigan.

It is the second high profile scientific appointment for Sanofi in recent weeks following the appointment of Dr Paul Chew to senior VP, chief medical officer and head of global medical affairs.

19th November 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics